Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2019 Jan 7. pii: AAC.02211-18. doi: 10.1128/AAC.02211-18. [Epub ahead of print]

Adjuvant β-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does β-lactam class matter?

Author information

1
Aurora Health Care, Department of Pharmacy Services, Milwaukee, WI, USA thomas.dilworth@aurora.org.
2
University of Florida College of Pharmacy, Jacksonville, FL, USA.
3
Independent Researcher, Gainesville, FL, USA.
4
University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA.
5
Washington State University College of Pharmacy and Pharmaceutical Sciences, Yakima, WA, USA.
6
University of Houston College of Pharmacy, Houston, TX, USA.
7
University of New Mexico College of Pharmacy, Albuquerque, NM, USA.

Abstract

We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (COMBO) on persistent methicillin-resistant Staphylococcus aureus bacteremia (≥5 days) compared to VAN using pooled data from two previously published, observational studies (n=156). COMBO was inversely associated with persistent bacteremia (adjusted odds ratio 0.460, 95% confidence interval, 0.229-0.923). Acute kidney injury was more common in COMBO than VAN (18.9% and 7.6%, respectively; p=0.062).

PMID:
30617094
DOI:
10.1128/AAC.02211-18

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center